Moderna (MRNA) on Solana

Moderna reported Q2 2026 revenue of $145 million, up 2% year-over-year and above the top of its guidance range, while cutting cash costs by 10% in the quarter. Net loss narrowed to $782 million ($1.97 per share) from $2.13 per share a year earlier. CEO Stéphane Bancel highlighted continued operating discipline, with R&D expenses down 7% to $651 million and cost of sales down 22% to $93 million. For full-year 2026, the company trimmed its cost-of-sales and R&D expense guidance by $100 million each and maintained a revenue growth target of "up to 10%," targeting a 50/50 U.S./international split.

On the pipeline, the mRNA-1010 influenza vaccine received a unanimous VRBPAC recommendation ahead of an August 5 PDUFA date, while mCOMBRIAX (flu/COVID combination) received EU approval. Moderna's COVID vaccine mNEXSPIKE captured approximately 24% of the U.S. retail COVID market. The company's personalized cancer vaccine candidate, intismeran, has a Phase III melanoma interim analysis expected in the second half of 2026, though the norovirus program (mRNA-1403) missed its Phase III early-success threshold, prompting enrollment of an additional cohort. Year-end cash and investments are projected at $4.7–5.2 billion.

The FDA approved Moderna's mFLUSIVA (mRNA-1010) on August 5, 2026, making it the company's fourth FDA-approved product and the first mRNA-based seasonal influenza vaccine to receive U.S. regulatory clearance. Approval covers adults aged 50 and older — full approval for the 50–64 age group based on Phase 3 clinical trial data from over 40,800 participants across 11 countries, and accelerated approval for adults 65 and older based on immunogenicity data pending confirmation of clinical benefit.

Moderna expects mFLUSIVA to be available at select U.S. retailers within weeks for the 2026–2027 respiratory season. Regulatory submissions in the European Union, Canada, and Australia are currently under review, with additional country filings planned. CEO Stéphane Bancel described the approval as demonstrating "the continued strength and versatility of our mRNA platform."

Moderna's norovirus vaccine candidate failed to meet early success criteria in a Phase 3 interim analysis, requiring the trial to continue for further evaluation — a setback to the company's effort to diversify its pipeline beyond COVID products. The result adds pipeline uncertainty for a company already reporting a net loss of $3.19 billion, with analysts noting that further clinical disappointments could weigh on sentiment and the company's funding outlook.

Against that backdrop, the FDA decision on MFLUSIVA — Moderna's seasonal influenza vaccine (mRNA-1010) — is expected by early August 2026 and stands as the most immediate catalyst in the near-term pipeline. Q2 results came in ahead of expectations and operating expense guidance was revised, offering some offset, but the norovirus miss underscores how much the company's broader valuation thesis now depends on approval and commercial traction in respiratory diseases beyond COVID.

Moderna (MRNA) fell more than 4% in premarket trading on July 31, 2026, even as the company reported second-quarter results that came in ahead of Wall Street estimates. The sell-the-news reaction placed Moderna among the biggest premarket movers in the broader market that morning, alongside names like Apple, Amazon, and Chevron.

The decline reflects a pattern seen in biotech and pharma stocks where earnings beats can still trigger selling if investors had priced in strong results or are rotating away from the sector. Moderna's Q2 performance continues to show recovery from its post-pandemic revenue trough, though the market's premarket response suggests caution about near-term catalysts and sustainability of its revenue trajectory beyond its core mRNA vaccine pipeline.

Moderna posted Q1 revenue of $389 million, a 260% year-over-year increase that topped analyst consensus by 55.8% — the strongest growth rate among a group of eleven tracked therapeutics companies. The broader sector also outperformed, beating revenue expectations by 14.5% on average with stocks up 9.4% since reporting, but Moderna's gains stood out sharply against peers including Amgen (+5.8%), Halozyme (+42.2%), and Novavax (-79.1% revenue decline). Moderna shares rose 17.5% in the period following the report.

Beyond the headline number, Moderna received two European regulatory approvals in the quarter, including mCOMBRIX — described as the world's first combined flu and COVID vaccine — and initiated a pivotal trial for a lung cancer treatment. CEO commentary highlighted significant cost reductions alongside the revenue growth, pointing to an operational profile that differs meaningfully from therapeutics peers still dependent on a single product cycle.

The FDA is expected to rule this week on Moderna's mRNA-1010, an experimental seasonal influenza vaccine targeting adults 50 and older. An independent advisory panel voted unanimously in June that the vaccine's benefits outweigh its risks, providing strong regulatory momentum ahead of the decision. The product uses the same mRNA platform behind Moderna's COVID-19 vaccines and is engineered to deliver enhanced protection for seniors, who face elevated risk of serious illness from influenza.

Approval would mark Moderna's first commercially available flu vaccine and open a recurring annual revenue stream, reducing the company's reliance on pandemic-driven COVID-19 sales. MRNA shares have fallen roughly 23% in the month leading up to the ruling, reflecting investor uncertainty. A favorable outcome would represent a significant expansion of Moderna's respiratory vaccine portfolio and validate its mRNA technology beyond its original COVID-19 franchise.

Moderna has appointed Michael McDonnell to its Board of Directors and Audit Committee, effective July 22, 2026. McDonnell is a veteran life-sciences CFO whose prior roles include chief financial officer at Biogen, IQVIA, and Intelsat, giving him direct experience overseeing capital allocation and investor communications at major public companies. Alongside his appointment, David Rubenstein transitioned from the Audit Committee to the Nominating and Corporate Governance Committee, reshuffling oversight responsibilities across the board.

The appointment reinforces financial oversight at a moment Moderna describes as a "complex product transition," with the company navigating mRNA pipeline expansion and cost discipline following its COVID-vaccine revenue peak. McDonnell's background in capital allocation and public-company financial strategy is expected to shape how the board evaluates partnerships and future opportunities heading into upcoming earnings.

Moderna (MRNA) shares fell roughly 11% on Friday to around $68, putting the stock on pace for its worst weekly performance in 11 months following a 48% surge in June that had briefly lifted the price above $85. The pullback is attributed to a combination of profit-taking and renewed caution from Wall Street analysts: Bank of America rates the stock Underperform with a $38 target, RBC Capital holds a Sector Perform at $45, and Morgan Stanley rates it Equal-Weight at $39 — all well below where shares traded at the peak of the June run.

Despite the weekly slide, MRNA remains up roughly 132% year-to-date, underpinned by the FDA advisory committee's unanimous 9-0 vote in favor of the company's mRNA seasonal flu vaccine (mRNA-1010), with a regulatory decision expected by August 5. Q2 earnings are due July 31, and investors are also watching late-stage cancer therapy data and updated European COVID-19 vaccine approvals as the next meaningful catalysts for the stock.

The European Commission signed a procurement contract for up to 24 million doses of Moderna's RSV vaccine, mRESVIA, to be delivered over four years across six EU member states. The agreement covers protection for adults against RSV-caused respiratory illnesses including bronchitis and pneumonia, and marks a meaningful commercial expansion for Moderna beyond its COVID-19 franchise. MRNA shares gained roughly 2.6–3.4% on the news, reaching approximately $76.52 in afternoon trading on July 10, 2026.

The deal provides multi-year revenue visibility for Moderna's mRNA platform and validates its RSV program in a major regulated market. The company is also advancing flu and norovirus vaccine candidates targeting 2027–2028 launches, making the EU RSV contract a milestone in its effort to establish a diversified respiratory vaccine portfolio.

Moderna shares have more than doubled in 2026 as investors reassess the company's trajectory beyond its COVID-19 origins. The most immediate catalyst is an FDA flu vaccine decision expected in early August, following a 9-0 advisory committee vote in favor of approval. Q1 2026 revenue came in at $389 million versus $108 million a year earlier, and the company holds roughly $7.5 billion in cash and investments, giving it a long runway despite still posting net losses. Management is guiding for up to 10% revenue growth in 2026 and cash breakeven by 2028.

The bull case centers on pipeline breadth: Moderna now has three commercial products and late-stage programs spanning a flu/COVID-19 combination vaccine, a norovirus vaccine, and a personalized cancer vaccine developed with Merck, with late-stage melanoma data still pending. Analysts writing in favor of the stock argue Moderna is no longer a single-product COVID play but is evolving into a diversified biotech with multiple near-term value creation opportunities. The key risk is binary: several large clinical readouts remain outstanding, and a disappointing result could quickly reverse sentiment in a stock that has already run sharply.